BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26289868)

  • 1. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 2. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
    Müller-Wieland D
    Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
    [No Abstract]   [Full Text] [Related]  

  • 3. [New cost saving legislation for drugs. National health insurance carriers do not want to believe Ulla Schmidt}].
    MMW Fortschr Med; 2006 Feb; 148(5):45. PubMed ID: 16518939
    [No Abstract]   [Full Text] [Related]  

  • 4. [New institute for additional drug evaluation. Do we really need another barrier?].
    Schmidt K
    MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
    [No Abstract]   [Full Text] [Related]  

  • 5. [Limited prescribing freedom by federal cost regulation?].
    Lasek R
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Consequences of the German AMNOG for the identification of study objectives to demonstrate clinical efficacy and cost effectiveness of innovative drugs].
    Götte D
    Dtsch Med Wochenschr; 2012 Feb; 137(6):274-80. PubMed ID: 22270904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Off-label therapy in rheumatology].
    Krüger K; Sieper J
    Z Rheumatol; 2012 Feb; 71(2):99-100. PubMed ID: 22370799
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 9. [New, expensive antidiabetics for the treatment of type-2 diabetes--contra].
    Nawroth P
    Dtsch Med Wochenschr; 2010 May; 135(18):923. PubMed ID: 20425679
    [No Abstract]   [Full Text] [Related]  

  • 10. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].
    Gallwitz B
    MMW Fortschr Med; 2014 Jul; 156(13):57-60. PubMed ID: 25318228
    [No Abstract]   [Full Text] [Related]  

  • 11. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
    Thöns M
    MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
    [No Abstract]   [Full Text] [Related]  

  • 12. [Investigation today for practice tomorrow].
    Klein H
    Dtsch Med Wochenschr; 2013 May; 138(18):933. PubMed ID: 23613370
    [No Abstract]   [Full Text] [Related]  

  • 13. [Biosimilars - Potential, risks and open questions].
    Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
    [No Abstract]   [Full Text] [Related]  

  • 14. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reform law endangers family physician reimbursement. Heavy loss cut of reduced utilization compensation].
    Schmidt K
    MMW Fortschr Med; 2007 Feb; 149(5):50, 53. PubMed ID: 17615733
    [No Abstract]   [Full Text] [Related]  

  • 17. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?].
    MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503
    [No Abstract]   [Full Text] [Related]  

  • 18. [The costs of new drugs compared to current standard treatment].
    Ujeyl M; Schlegel C; Gundert-Remy U
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(7):461-7. PubMed ID: 24238023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What must now be addressed in health policy].
    Braun LG; Gürkan I; Jacobs P; Räsch RJ; Walter N
    Chirurg; 2003 Feb; 74(2):M41-4. PubMed ID: 12691061
    [No Abstract]   [Full Text] [Related]  

  • 20. [Regresses for medicine prescription: benchmark evaluations should be eliminated].
    Dryden WA
    MMW Fortschr Med; 2013 Nov; 155 Spec No 2():16. PubMed ID: 24734441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.